Tang Shao Hui, Yang Dong Hua, Huang Wei, Zhou Hong Ke, Lu Xiao Hua, Ye Gang
Department of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou, China.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4171-7. doi: 10.1158/1078-0432.CCR-05-2261.
The expression of human insulin-like growth factor-II (IGF-II) is regulated by the activation of four promoters (P1-P4) acting in a development-dependent, tissue-specific manner. IGF-II overexpression associated with P3 and P4 activation is observed in animal and human hepatocarcinogenesis. We correlated P4 epigenetic alteration with P4 transcript activation and clinicopathologic features.
We analyzed P4 epigenetic alteration using methylation-specific PCR in 34 hepatocellular carcinoma (HCC) specimens, 34 matched adjacent nontumor specimens, and 8 normal adult liver specimens. The data were correlated with activation of P4 transcription by using reverse transcription-PCR. Epigenetic alteration was compared with patients' clinicopathologic features.
Compared with normal liver tissue, hypomethylation of P4 CpG islands was significantly more frequent in HCC (P = 0.03) and matched tissues (P = 0.047). P4 mRNA levels in HCC with unmethylated alleles were significantly higher than in HCC without unmethylated alleles (P = 0.001); P4 mRNA levels in matched nontumor tissues with unmethylated alleles were significantly higher than in matched nontumor tissues without unmethylated alleles (P = 0.005). P4 hypomethylation in HCC was associated with portal vein tumor embolus (P = 0.017) and poorer tumor differentiation (P = 0.025).
These findings suggest that IGF-II P4 hypomethylation may be an early and frequent event and that it may contribute to P4 transcription expression activation during the transformation of a premalignant liver lesion to HCC. Furthermore, aberrant hypomethylation of P4 CpG islands not only may play an important role during hepatocarcinogenesis but might also be a useful biomarker for poor prognosis of patients with HCC.
人类胰岛素样生长因子-II(IGF-II)的表达受四个启动子(P1 - P4)的激活调控,这些启动子以发育依赖性、组织特异性方式发挥作用。在动物和人类肝癌发生过程中,观察到与P3和P4激活相关的IGF-II过表达。我们将P4表观遗传改变与P4转录激活及临床病理特征进行关联分析。
我们使用甲基化特异性PCR分析了34例肝细胞癌(HCC)标本、34例配对的相邻非肿瘤标本和8例正常成人肝脏标本中的P4表观遗传改变。通过逆转录PCR将数据与P4转录激活相关联。将表观遗传改变与患者的临床病理特征进行比较。
与正常肝组织相比,P4 CpG岛的低甲基化在HCC(P = 0.03)和配对组织(P = 0.047)中明显更常见。等位基因未甲基化的HCC中P4 mRNA水平显著高于等位基因未甲基化的HCC(P = 0.001);等位基因未甲基化的配对非肿瘤组织中P4 mRNA水平显著高于等位基因未甲基化的配对非肿瘤组织(P = 0.005)。HCC中的P4低甲基化与门静脉癌栓(P = 0.017)和较差的肿瘤分化(P = 0.025)相关。
这些发现表明IGF-II P4低甲基化可能是一个早期且常见的事件,并且它可能在癌前肝病变向HCC转化过程中促进P4转录表达激活。此外,P4 CpG岛的异常低甲基化不仅可能在肝癌发生过程中起重要作用,还可能是HCC患者预后不良的有用生物标志物。